PPD and SNBL Announce Japanese Joint Venture
PPD and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture.
Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture, PPD-SNBL, that will provide clinical development services in Japan. Some of these services include Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
PPD-SNBL will combine SNBL’s clinical research division and PPD’s clinical development operations in Japan, and it will have offices in Tokyo, Osaka, and Kagoshima The transactions are subject to customary closing conditions and are expected to close in April 2015.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025